Lincoln Pharmaceuticals Limited

NSE: LINCOLN · Unclassified

₹507.55-0.98%06 Nov 2026

Ask the data

Instant answers about Lincoln Pharmaceuticals Limited — computed from its filings, no language model

Market cap₹1,017 cr

Current price₹507.55

High / Low₹758 / ₹444

P/E—

P/B1.25

Book value₹405.2

ROE0.0%

ROCE15.8%

Debt / equity0.00

Dividend yield0.36%

EPS (TTM)₹0.00

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY18	FY23	FY24	FY25	FY26
Revenue	361.6	510.3	580.5	623.2	671.0
EBITDA	52.3	89.2	99.9	101.5	97.7
Operating margin	14.5%	17.5%	17.2%	16.3%	14.6%
Interest	5.4	2.0	1.5	1.9	1.0
Depreciation	6.1	9.2	10.6	12.9	14.5
Profit before tax	46.2	100.5	122.2	109.2	115.6
Tax	11.6	27.6	28.9	26.8	27.7
Net profit	34.6	0.0	0.0	0.0	0.0
EPS ₹	17.32	36.40	46.58	41.11	43.88
Operating cash flow	—	39.3	63.2	93.0	106.4
Capex	—	14.3	39.5	19.0	26.0
Dividend paid	—	3.0	3.0	3.6	3.6
Total assets	—	587.4	700.3	797.0	890.4
Equity	—	502.5	592.8	671.7	757.6

Quarterly performance

last 25 quarters · ₹ crore

showing latest 8 of 25 periods

	MAR '18	SEP '18	DEC '18	DEC '19	JUN '20	SEP '20	DEC '21	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	67.1	102.6	84.4	98.5	103.8	126.1	119.9	123.5	140.6	133.8	112.5	135.6	156.0	146.4	142.5	147.3	161.2	146.6	168.2	154.1	163.4	166.3	187.3	177.3	191.3
Operating profit	9.7	19.1	13.6	13.2	22.2	29.8	23.4	16.9	28.9	26.8	16.6	20.7	31.1	29.7	18.4	22.7	28.4	23.7	26.7	23.8	25.4	23.6	24.9	27.4	23.7
Operating margin	14.4%	18.6%	16.1%	13.4%	21.4%	23.6%	19.6%	13.7%	20.6%	20.0%	14.8%	15.3%	20.0%	20.3%	12.9%	15.4%	17.6%	16.1%	15.9%	15.4%	15.6%	14.2%	13.3%	15.5%	12.4%
Other income	0.9	4.4	0.4	3.0	1.8	0.6	2.6	6.5	5.7	6.4	3.9	7.7	8.7	11.0	7.0	10.4	10.0	9.0	-6.9	15.3	7.2	15.2	-4.2	24.3	9.5
Interest	0.9	1.8	0.7	1.4	0.7	-0.1	0.3	0.4	0.1	0.3	1.1	0.4	0.4	0.1	0.5	0.4	0.3	0.7	0.4	0.2	0.2	0.3	0.3	0.3	0.3
Depreciation	1.5	1.5	1.9	1.9	1.9	1.9	2.2	2.1	2.4	2.3	2.4	2.5	2.6	2.8	2.7	3.2	3.2	3.2	3.2	3.5	3.6	3.7	3.7	3.9	3.9
Profit before tax	8.0	20.3	11.3	13.0	21.4	28.6	23.6	20.9	32.1	30.5	17.0	25.4	36.9	37.7	22.2	29.5	34.8	28.7	16.2	35.4	28.8	34.7	16.7	47.5	29.0
Tax	1.2	5.2	2.2	2.1	6.2	7.6	6.0	5.9	8.3	8.9	4.4	6.4	9.2	9.7	3.6	5.8	8.4	7.9	4.7	7.7	8.8	6.1	5.1	11.3	8.6
Net profit	6.8	0.0	0.0	10.9	15.3	20.9	17.6	15.0	0.0	21.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EPS ₹	3.41	7.50	4.57	5.46	7.63	10.46	8.79	7.49	11.84	10.79	6.27	9.49	13.81	14.00	9.28	11.82	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09	10.20
Revenue YoY	—	—	—	16.7%	—	—	—	—	—	11.6%	—	9.8%	10.9%	9.5%	26.7%	8.6%	3.3%	0.1%	18.0%	4.6%	1.3%	13.5%	11.4%	15.1%	17.1%
Profit YoY	—	—	—	—	—	—	—	—	—	22.8%	—	-100.0%	—	-100.0%	—	—	—	—	—	—	—	—	—	—	—

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Lincoln Pharmaceuticals Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	114.4	125.9	178.7	175.7	193.0	209.9	228.6	317.1	306.6
Operating profit	9.7	9.8	12.9	14.7	18.6	20.2	28.4	38.8	44.2
Operating margin	8.4%	7.8%	7.2%	8.3%	9.6%	9.6%	12.4%	12.2%	14.4%
Other income	0.2	1.4	0.0	—	—	—	—	—	—
Interest	2.0	2.4	3.2	6.7	5.2	5.4	6.3	5.5	5.4
Depreciation	0.8	0.9	1.7	1.9	2.1	2.3	2.9	3.2	3.9
Profit before tax	7.1	7.9	8.0	7.6	11.3	12.5	19.2	30.1	34.2
Tax	0.0	0.0	1.3	2.7	1.5	1.1	4.4	8.3	8.9
Net profit	7.1	7.9	6.7	4.9	9.8	11.4	14.8	21.8	25.3

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	20.9	22.4	26.0	28.9	35.8	28.0	21.8	30.9	32.0	33.6	29.5	32.5	44.6	40.6	61.0	37.0	46.1	50.8	41.8	30.2	53.7	49.7	59.4	39.2	55.5	52.0	63.1	48.3	59.8	59.3	61.2	60.7	78.8	82.7	94.9	79.5	73.1	66.0	88.0	87.2	85.6	75.6
Operating profit	2.4	3.2	0.1	1.9	3.7	3.0	1.0	2.9	3.2	2.2	1.4	2.8	4.6	1.7	3.7	2.4	6.1	2.9	3.3	3.0	6.4	3.4	5.7	4.3	5.1	7.0	3.8	7.2	9.9	5.6	5.8	9.9	9.2	10.5	9.2	16.1	12.3	8.9	6.8	5.8	13.0	14.7
Operating margin	11.5%	14.1%	0.3%	6.7%	10.4%	10.9%	4.5%	9.3%	10.0%	6.7%	4.9%	8.7%	10.4%	4.1%	6.1%	6.5%	13.2%	5.6%	7.9%	10.1%	11.9%	6.9%	9.7%	11.0%	9.1%	13.5%	6.0%	14.8%	16.6%	9.4%	9.4%	16.3%	11.6%	12.7%	9.7%	20.2%	16.9%	13.6%	7.8%	6.7%	15.2%	19.5%
Other income	0.1	0.2	0.6	0.1	-0.0	0.4	-0.3	0.2	0.1	0.7	0.4	0.3	0.6	0.6	-1.6	0.6	1.0	0.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.7	2.6	2.9	2.7
Interest	0.3	0.3	0.4	0.3	0.6	0.3	0.8	0.6	0.4	0.6	0.8	0.8	1.0	1.4	0.0	0.9	2.3	1.7	1.7	1.0	1.1	1.1	1.9	0.9	0.5	1.7	2.3	1.4	1.5	1.2	2.3	1.5	1.4	1.6	1.1	1.6	1.3	1.0	1.4	1.2	1.0	0.9
Depreciation	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.4	0.1	0.2	0.2	0.3	0.4	0.4	0.6	0.4	0.4	0.5	0.6	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.7	0.9	0.7	0.6	0.7	0.7	0.9	0.9	1.0	0.9	1.0	1.0	1.0	1.4	1.0
Profit before tax	2.0	2.9	0.1	1.6	3.0	2.9	-0.4	2.1	2.8	2.2	0.8	2.1	3.9	0.5	1.6	1.7	4.3	0.7	0.9	1.5	4.7	1.8	3.3	2.8	4.0	4.7	1.0	5.1	7.5	3.7	2.9	7.7	7.1	8.1	7.2	13.5	10.2	6.9	3.7	6.2	13.5	15.5
Tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	-0.3	0.5	-0.3	2.5	0.3	0.2	0.4	1.2	-0.2	0.1	-0.7	0.5	0.9	0.4	1.2	1.3	0.9	1.0	1.6	1.6	3.0	2.1	3.3	2.4	2.0	1.2	1.7	3.6	4.4
Net profit	2.0	2.9	0.1	1.6	3.0	2.9	-0.4	2.1	2.8	2.2	0.8	2.1	2.8	0.8	1.1	1.9	1.8	0.5	0.8	1.1	3.5	2.0	3.2	3.5	3.5	3.8	0.6	3.9	6.2	2.8	1.9	6.1	5.4	5.1	5.1	10.2	7.8	4.9	2.4	4.5	9.9	11.1
EPS ₹	2.13	—	—	1.64	3.11	3.08	-0.50	10.84	14.63	8.77	2.96	7.28	2.43	0.47	0.81	1.20	1.07	0.27	0.05	0.69	2.17	1.21	1.95	2.15	2.16	2.35	0.35	2.36	3.81	1.72	1.17	3.73	3.33	3.10	3.05	6.23	4.50	2.61	1.22	2.24	4.97	5.57
Revenue YoY	—	—	—	—	71.5%	25.0%	-16.5%	6.7%	-10.6%	20.1%	35.5%	5.2%	39.4%	20.9%	107.0%	14.0%	3.5%	25.1%	-31.5%	-18.3%	16.4%	-2.2%	42.1%	29.8%	3.4%	4.6%	6.4%	23.2%	7.7%	14.1%	-3.1%	25.5%	31.9%	39.4%	55.1%	31.1%	-7.3%	-20.2%	-7.2%	9.6%	17.1%	14.5%
Profit YoY	—	—	—	—	45.8%	1.4%	-533.3%	32.1%	-6.1%	-25.3%	—	0.0%	-1.1%	-65.3%	33.3%	-5.3%	-36.4%	-40.8%	-32.1%	-42.6%	102.3%	337.8%	318.4%	212.5%	-0.6%	94.4%	-81.8%	10.0%	76.4%	-26.9%	229.3%	57.9%	-12.6%	83.6%	167.0%	66.9%	42.7%	-3.9%	-52.2%	-55.7%	28.1%	125.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 15 periods

	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	7.3%	4.3%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ROCE	20.3%	21.2%	20.5%	21.8%	20.8%	21.5%	19.6%	18.3%	16.5%	17.4%	15.5%	16.2%	15.3%	16.9%	15.8%
Net margin	7.2%	4.1%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBITDA margin	17.5%	17.8%	17.7%	17.8%	17.2%	17.2%	16.6%	15.6%	16.3%	16.3%	15.8%	15.3%	14.6%	14.6%	13.8%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00
Interest coverage	50.50	52.47	48.95	56.45	84.73	86.32	87.24	58.01	58.77	70.34	71.86	104.76	115.48	121.55	112.30
Asset turnover	0.87	0.89	0.81	0.83	0.83	0.85	0.77	0.77	0.78	0.79	0.74	0.76	0.75	0.78	0.75

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0	20.0
Other equity / reserves	448.6	482.4	526.0	572.8	619.2	651.6	695.7	737.6	791.5
Total equity	468.7	502.5	546.0	592.8	639.3	671.7	715.8	757.6	811.5
Borrowings	12.0	2.0	0.9	1.1	1.4	0.0	0.1	4.4	3.4
Current liabilities	123.7	72.3	103.2	92.3	120.4	106.2	115.9	111.0	126.6
Non-current liabilities	11.1	12.7	14.1	15.2	20.1	19.1	22.8	21.7	26.1
Total assets	603.4	587.4	663.3	700.3	779.8	797.0	854.5	890.4	964.2
Property, plant & equipment	130.2	150.2	147.0	179.0	176.8	181.5	184.1	190.0	189.8
Capital work-in-progress	23.1	6.7	9.1	3.5	6.6	4.5	3.1	5.2	6.7
Investments	101.2	91.3	132.3	138.9	164.5	173.7	208.9	208.5	244.6
Inventories	78.8	70.0	65.6	77.2	84.8	78.7	80.8	80.1	81.7
Receivables	173.9	136.3	173.1	161.8	178.4	166.4	169.8	161.4	164.4
Cash & equivalents	3.6	5.0	15.2	5.8	10.1	13.4	20.3	21.5	21.3

Cash flow

annual · ₹ crore · line = free cash flow

	FY23	FY24	FY25	FY26
Cash from operations	39.3	63.2	93.0	106.4
Cash from investing	-36.6	-57.3	-79.0	-98.4
Cash from financing	-4.5	-5.2	-6.4	0.2
Capex	14.3	39.5	19.0	26.0
Free cash flow	25.0	23.7	74.0	80.3
Dividends paid	3.0	3.0	3.6	3.6

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹189.8 cr20%

CWIP

₹6.7 cr1%

Investments

₹244.6 cr25%

Inventories

₹81.7 cr8%

Receivables

₹164.4 cr17%

Cash & equivalents

₹21.3 cr2%

Other assets

₹255.7 cr27%

Peer comparison

largest in Unclassified · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Avantel Limited	36,86,04,549	138.69	—	1059360.68	0.0%
Ducol Organics And Colours Limited	19,55,275	120.00	—	20089.13	0.0%
Jio Platforms Limited	12,57,181	1,406.40	—	3.57	—
SBI Funds Management Limited	1,01,750	499.55	—	—	—
Tamilnadu Telecommunication Limited	91,314	9.93	—	—	—
Manipal Health Enterprises Limited	76,294	646.70	—	—	—
INDO-MIM Limited	59,042	1,219.50	—	—	—
AvenuesAI Limited	45,138	129.25	153.6	9.51	6.2%
Dhoot Transmission Limited	32,761	1,601.60	—	8.11	—
3M India Limited	31,071	27,570.00	53.8	17.57	32.7%
Lincoln Pharmaceuticals Limited	1,017	507.55	—	1.25	0.0%

StoxGud checklist: Bearish setup · 2/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-10.0%

6 months-24.3%

1 year-4.8%

3Y CAGR-2.6%

5Y CAGR+7.6%

10Y CAGR+8.9%

50-day avg₹572.73

200-day avg₹593.97

RSI (14)39

FAQs

What is the share price of Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited (LINCOLN) closed at ₹507.55 on NSE on 06 Nov 2026.

What is the market cap of Lincoln Pharmaceuticals Limited?

₹1,017 crore at the latest close.

How fast is Lincoln Pharmaceuticals Limited growing?

Lincoln Pharmaceuticals Limited: revenue has compounded at 9.6% a year over three years. Latest-quarter revenue is up 17.1% year on year.

How profitable is Lincoln Pharmaceuticals Limited?

On a trailing-twelve-month basis return on equity is 0.0%, return on capital employed 15.8%, operating margin 13.8%, net margin 0.0%.

How much debt does Lincoln Pharmaceuticals Limited have?

Lincoln Pharmaceuticals Limited is debt-free: debt to equity is 0.00 with borrowings of ₹3 cr against cash of ₹21 cr (balance sheet of 2026-09-30). Operating profit covers interest 112.3 times.

Financials parsed from Lincoln Pharmaceuticals Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.